Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05852691 | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 83 | Hoffmann-La RocheINDUSTRY | 16 | Sep 10, 2026 | clinicaltrials |
| NCT06797635 | Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | recruiting | Phase 2 | 372 | Merck Sharp & Dohme LLC |
| 4 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT07638852 | Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.(ABC-R) | recruiting | Phase 2 | 58 | Fudan UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07766018 | A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 70 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811232 | A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03606967 | Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04001829 | Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer | active not recruiting | Phase 2 | 249 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05226871 | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | active not recruiting | Phase 2 | 35 | PfizerINDUSTRY | 7 | Sep 9, 2026 | clinicaltrials |
| NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer(ELECTRA) | recruiting | Phase 1 / Phase 2 | 73 | Stemline Therapeutics, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT05570253 | A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | recruiting | Phase 2 | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06966453 | A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 74 | PfizerINDUSTRY | 9 | Sep 9, 2026 | clinicaltrials |
| NCT07100106 | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer(MoonROSE) | recruiting | Phase 1 / Phase 2 | 285 | Genentech, Inc.INDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT07405801 | A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer | recruiting | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT05192798 | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | recruiting | Phase 2 | 128 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06062498 | Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 174 | Northwestern UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06298084 | Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd(ICARUSBREAST02) | recruiting | Phase 1 / Phase 2 | 152 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07287917 | Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 92 | Aminex Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07368998 | To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer(optINAVO) | recruiting | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT04886531 | Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | recruiting | Phase 2 | 30 | Ruth O'ReganOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05846789 | Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers | recruiting | Phase 2 | 168 | Kathy MillerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06245889 | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC(NeoADAPT) | recruiting | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06635980 | Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer | recruiting | Phase 2 | 120 | Mayo ClinicOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06649331 | Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06902311 | Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)(H-ASSIST) | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07413939 | RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive(BREnnA) | recruiting | Phase 2 / Phase 3 | 650 | Hoffmann-La RocheINDUSTRY | 25 | Sep 3, 2026 | clinicaltrials |
| NCT07801898 | Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer | not yet recruiting | Phase 2 | 36 | The Second Hospital of Anhui Medical UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03946202 | KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer | active not recruiting | Phase 2 | 184 | Institute of Cancer Research, United KingdomOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05548127 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | active not recruiting | Phase 1 / Phase 2 | 37 | PfizerINDUSTRY | 4 | Sep 2, 2026 | clinicaltrials |
| NCT07789912 | BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies(BRAVO-LM) | not yet recruiting | Phase 2 | 40 | University of MiamiOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02955394 | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | active not recruiting | Phase 2 | 61 | University of Colorado, DenverOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05460273 | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) | active not recruiting | Phase 1 / Phase 2 | 119 | AstraZenecaINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06086704 | Study of 18F-FFNP Breast PET/MRI | recruiting | Phase 2 | 53 | University of Wisconsin, MadisonOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT06460298 | ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 51 | ProDa BioTech, LLCINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07795424 | Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer | not yet recruiting | Phase 2 | 33 | Shengjing HospitalOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02311933 | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02849496 | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | active not recruiting | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04677816 | Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients | recruiting | Phase 2 | 50 | Wake Forest University Health SciencesOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06068985 | Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade(CHERRY-PICK) | active not recruiting | Phase 2 | 63 | Latin American Cooperative Oncology GroupOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06428396 | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | active not recruiting | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Aug 28, 2026 | clinicaltrials |
| NCT05716893 | Study of Aerobic Training for People Receiving Treatment for Breast Cancer | recruiting | Phase 2 | 140 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04430595 | Multi-4SCAR-T Therapy Targeting Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 100 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06533826 | TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd(TRADE DXd) | recruiting | Phase 2 | 357 | Ana C Garrido-Castro, MDOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06891833 | A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer | recruiting | Phase 2 / Phase 3 | 985 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07109817 | Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer(DETOXp) | recruiting | Phase 2 | 116 | Montefiore Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07222215 | PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)(CAPELA) | recruiting | Phase 2 | 297 | Kristina A. FanucciOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07782840 | QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 | 40 | Hebei Medical University Fourth HospitalOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07786428 | Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBC(DETENTE-1) | not yet recruiting | Phase 2 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials